SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Amazon Natural (AZNT)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Graystone who wrote (6240)9/18/1998 10:43:00 AM
From: bmart  Read Replies (2) of 26163
 
biz.yahoo.com

Thursday September 17, 10:36 pm Eastern Time

HemispheRx could see decline in stock - BW

NEW YORK, Sept 17 (Reuters) - A number of short-sellers are betting that the
potential of biotech company HemispheRx BioPharma to produce an effective
treatment for Chronic Fatigue Syndrome has been overstated, according to one
analyst in the September 28 edition of Business Week.

Manuel Asensio, head of investment company Asensio & Co. told Business Week's
Inside Wall Street column he is shorting the stock with a target price of
zero.

Asensio believes HemispheRx's ampligen chronic fatigue drug is neither safe
nor
effective.
The company's Chief Executive William Carter told Business Week the drug's
safety and effectiveness have been well established.

Asensio also said the company's shares are subject to substantial dilution
from
as-yet-unexercised warrants, options, and convertible preferred stock.

Asensio calculates that when exercised, they will boost the number of shares
outstanding by more than 80 percent.

A HempispheRx spokesperson confirmed his contention, Business Week said.
Carter told the magazine that he doesn't believe there will be a substantial
dilutive effect.

Shares of HemispheRx closed at 9- Thursday, down 7/16.
The stock's year high is 13-3/16.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News